
Beom Seok Jeon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8373859/publications.pdf Version: 2024-02-01



REOM SEOK LEON

#	Article	IF	CITATIONS
1	Clinical Spectrum of Dopa-Responsive Dystonia and Related Disorders. Current Neurology and Neuroscience Reports, 2014, 14, 461.	4.2	118
2	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	10.2	116
3	Automatic Classification of Tremor Severity in Parkinson's Disease Using a Wearable Device. Sensors, 2017, 17, 2067.	3.8	109
4	Wrist sensor-based tremor severity quantification in Parkinson's disease using convolutional neural network. Computers in Biology and Medicine, 2018, 95, 140-146.	7.0	85
5	Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. Neurology, 2018, 91, e1003-e1012.	1.1	85
6	A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism. Frontiers in Neurology, 2018, 9, 1021.	2.4	82
7	Peripheral blood inflammatory markers in early Parkinson's disease. Journal of Clinical Neuroscience, 2018, 58, 30-33.	1.5	73
8	Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 26, 47-54.	2.2	62
9	Nervous system involvement by metastatic hepatocellular carcinoma. Journal of Neuro-Oncology, 1998, 36, 85-90.	2.9	61
10	Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. Parkinsonism and Related Disorders, 2018, 51, 49-54.	2.2	61
11	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	2.8	56
12	Optical Coherence Tomography in Parkinson's Disease: Is the Retina a Biomarker?. Journal of Parkinson's Disease, 2014, 4, 197-204.	2.8	55
13	Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes. Radiology, 2021, 300, 260-278.	7.3	55
14	ELECTRODE POSITION DETERMINED BY FUSED IMAGES OF PREOPERATIVE AND POSTOPERATIVE MAGNETIC RESONANCE IMAGING AND SURGICAL OUTCOME AFTER SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION. Neurosurgery, 2008, 63, 925-937.	1.1	54
15	Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. Journal of the Neurological Sciences, 2019, 401, 81-86.	0.6	49
16	CSF β-amyloid ₄₂ and risk of freezing of gait in early Parkinson disease. Neurology, 2019, 92, e40-e47.	1.1	45
17	Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nature Reviews Neurology, 2022, 18, 203-220.	10.1	44
18	REM sleep behavior disorder portends poor prognosis in Parkinson's disease: A systematic review. Journal of Clinical Neuroscience, 2018, 47, 6-13.	1.5	43

#	Article	IF	CITATIONS
19	Mitochondrial <i>UQCRC1</i> mutations cause autosomal dominant parkinsonism with polyneuropathy. Brain, 2020, 143, 3352-3373.	7.6	37
20	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission, 2021, 128, 321-335.	2.8	37
21	Whole-Brain Diffusion-Tensor Changes in Parkinsonian Patients with Impulse Control Disorders.		

#	Article	IF	CITATIONS
37	The Pathogenic Role of Low Range Repeats in SCA17. PLoS ONE, 2015, 10, e0135275.	2.5	23
38	Expanding the Spectrum of Dopa-Responsive Dystonia (DRD) and Proposal for New Definition: DRD, DRD-plus, and DRD Look-alike. Journal of Korean Medical Science, 2018, 33, e184.	2.5	23
39	A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 3-8.	2.2	22
40	Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease. Parkinsonism and Related Disorders, 2019, 58, 35-39.	2.2	22
41	Quantitative Gait Analysis Using a Pose-Estimation Algorithm with a Single 2D-Video of Parkinson's Disease Patients. Journal of Parkinson's Disease, 2021, 11, 1271-1283.	2.8	22
42	STN DBS of Advanced Parkinson's Disease Experienced in a Specialized Monitoring Unit with a Prospective Protocol. Journal of Korean Neurosurgical Society, 2008, 44, 26.	1.2	22
43	Clinical Heterogeneity of Atypical Pantothenate Kinase-Associated Neurodegeneration in Koreans. Journal of Movement Disorders, 2016, 9, 20-27.	1.3	21
44	Delayed facial palsy after microvascular decompression for hemifacial spasm: friend or foe?. Journal of Neurosurgery, 2018, 129, 299-307.	1.6	20
45	Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinson's disease. PLoS ONE, 2019, 14, e0221219.	2.5	20
46	Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder. Neurology, 2021, 97, e378-e388.	1.1	20
47	Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies. Journal of Movement Disorders, 2020, 13, 11-19.	1.3	20
48	Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis. Parkinsonism and Related Disorders, 2016, 29, 83-89.	2.2	19
49	Dry facts are not always inviting: a content analysis of Korean videos regarding Parkinson's disease on YouTube. Journal of Clinical Neuroscience, 2017, 46, 167-170.	1.5	19
50	Identifying the Clusters within Nonmotor Manifestations in Early Parkinson's Disease by Using Unsupervised Cluster Analysis. PLoS ONE, 2014, 9, e91906.	2.5	19
51	A Systematic Review of Treatment Outcome in Patients with Dopaâ€responsive Dystonia (<scp>DRD</scp>) and <scp>DRD</scp> â€Plus. Movement Disorders Clinical Practice, 2016, 3, 435-442.	1.5	18
52	Peripheral Blood Inflammatory Cytokines in Idiopathic REM Sleep Behavior Disorder. Movement Disorders, 2019, 34, 1739-1744.	3.9	18
53	Progression of Oropharyngeal Dysphagia in Patients with Multiple System Atrophy. Dysphagia, 2020, 35, 24-31.	1.8	18
54	Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorderâ€Related Metabolic Pattern Expression. Movement Disorders, 2021, 36, 1889-1898.	3.9	18

#	Article	IF	CITATIONS
55	Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinson's Disease. Journal of Movement Disorders, 2018, 11, 30-34.	1.3	18
56	SCA2 family presenting as typical Parkinson's disease: 34 year follow up. Parkinsonism and Related Disorders, 2017, 40, 69-72.	2.2	16
57	Nonmotor Effects of Conventional and Transdermal Dopaminergic Therapies in Parkinson's Disease. International Review of Neurobiology, 2017, 134, 989-1018.	2.0	16
58	Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 30-37.	1.9	16
59	Association of Physical Activity and <i>APOE</i> Genotype With Longitudinal Cognitive Change in Early Parkinson Disease. Neurology, 2021, 96, e2429-e2437.	1.1	16
60	Long-Term Clinical Outcome of Internal Globus Pallidus Deep Brain Stimulation for Dystonia. PLoS ONE, 2016, 11, e0146644.	2.5	16
61	A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea. Parkinsonism and Related Disorders, 2016, 22, 106-107.	2.2	15
62	The association between vertebrobasilar dolichoectasia and hemifacial spasm. Parkinsonism and Related Disorders, 2016, 32, 54-59.	2.2	15
63	Sex differences in the short-term and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 68, 73-78.	2.2	15
64	Comparison of sleep and other non-motor symptoms between SWEDDs patients and de novo Parkinson's disease patients. Parkinsonism and Related Disorders, 2014, 20, 1419-1422.	2.2	14
65	Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study. BMC Neurology, 2015, 15, 17.	1.8	14
66	Professional ethics in complementary andÂalternative medicines in management ofÂParkinson's disease. Journal of Parkinson's Disease, 2016, 6, 675-683.	2.8	14
67	Various Motor and Non-Motor Symptoms in Early Multiple System Atrophy. Neurodegenerative Diseases, 2019, 19, 238-243.	1.4	14
68	Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial. Journal of Movement Disorders, 2018, 11, 65-71.	1.3	14
69	Apolipoprotein E Îμ4 genotype and risk of freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 81, 173-178.	2.2	13
70	Bilateral Deep Brain Stimulation of the Subthalamic Nucleus under Sedation with Propofol and Fentanyl. PLoS ONE, 2016, 11, e0152619.	2.5	12
71	Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients. Npj Parkinson's Disease, 2016, 2, 16020.	5.3	12
72	Emergence of non-motor fluctuations with reference to motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 54, 79-83.	2.2	12

#	Article	IF	CITATIONS
73	Macular ganglion-cell-complex layer thinning and optic nerve integrity in drug-naÃ⁻ve Parkinson's disease. Journal of Neural Transmission, 2019, 126, 1695-1699.	2.8	12
74	Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease. Movement Disorders, 2022, 37, 1535-1541.	3.9	12
75	The Good, the Bad, and the Ugly of Medical Information on the Internet. Movement Disorders, 2018, 33, 754-757.	3.9	11
76	Objective measurement of limb bradykinesia using a marker-less tracking algorithm with 2D-video in PD patients. Parkinsonism and Related Disorders, 2020, 81, 129-135.	2.2	11
77	Preliminary Analysis of Huntington's Disease in South Korea. Journal of Huntington's Disease, 2013, 2, 83-87.	1.9	10
78	Maladaptive Reward-Learning and Impulse Control Disorders in Patients with Parkinson's Disease: A Clinical Overview and Pathophysiology Update. Journal of Movement Disorders, 2014, 7, 67-76.	1.3	10
79	Depression may negatively affect the change in freezing of gait following subthalamic nucleus stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 133-136.	2.2	10
80	Decision under risk: Argument against early deep brain stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 7-10.	2.2	10
81	Successful Pallidal Deep Brain Stimulation in a Patient with Childhood-Onset Generalized Dystonia with ANO3 Mutation. Journal of Movement Disorders, 2019, 12, 190-191.	1.3	10
82	Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications. Journal of the Neurological Sciences, 2017, 377, 6-11.	0.6	9
83	Psychiatric symptoms in myoclonus-dystonia syndrome are just concomitant features regardless of the SGCE gene mutation. Parkinsonism and Related Disorders, 2017, 42, 73-77.	2.2	9
84	REM sleep behavior disorder predicts functional dependency in early Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 138-142.	2.2	9
85	Unsupervised clustering of dopamine transporter <scp>PET</scp> imaging discovers heterogeneity of parkinsonism. Human Brain Mapping, 2020, 41, 4744-4752.	3.6	9
86	Bilateral Subthalamic Nucleus Deep Brain Stimulation under General Anesthesia: Literature Review and Single Center Experience. Journal of Clinical Medicine, 2020, 9, 3044.	2.4	9
87	Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson's Disease. Journal of Movement Disorders, 2018, 11, 133-138.	1.3	9
88	Preferential microglial activation associated with pathological alpha synuclein transmission. Journal of Clinical Neuroscience, 2020, 81, 469-476.	1.5	8
89	Urinary Symptoms and Urodynamic Findings in Patients with Spinocerebellar Ataxia. Cerebellum, 2020, 19, 483-486.	2.5	8
90	Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East. Journal of Parkinson's Disease, 2020, 10, 729-741.	2.8	8

#	Article	IF	CITATIONS
91	Clinical outcome prediction from analysis of microelectrode recordings using deep learning in subthalamic deep brain stimulation for Parkinson`s disease. PLoS ONE, 2021, 16, e0244133.	2.5	8
92	Functional Characterization of Rare RAB12 Variants and Their Role in Musician's and Other Dystonias. Genes, 2017, 8, 276.	2.4	7
93	Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875931.	3.5	7
94	Alpha-synuclein staining in non-neural structures of the gastrointestinal tract is non-specific in Parkinson disease. Parkinsonism and Related Disorders, 2018, 55, 15-17.	2.2	7
95	Does peripheral inflammation contribute to multiple system atrophy?. Parkinsonism and Related Disorders, 2019, 64, 340-341.	2.2	7
96	Serum TNF-α and neurodegeneration in isolated REM sleep behavior disorder. Parkinsonism and Related Disorders, 2020, 81, 1-7.	2.2	7
97	Eye movements and association with regional brain atrophy in clinical subtypes of progressive supranuclear palsy. Journal of Neurology, 2021, 268, 967-977.	3.6	7
98	Parafoveal Change and Dopamine Loss in the Retina with Parkinson's Disease. Annals of Neurology, 2021, 89, 421-422.	5.3	7
99	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. Parkinsonism and Related Disorders, 2021, 82, 146-149.	2.2	7
100	Impact of the apolipoprotein E ε4 allele on early Parkinson's disease progression. Parkinsonism and Related Disorders, 2021, 83, 66-70.	2.2	7
101	Mild cognitive impairment and abnormal brain metabolic expression in idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2021, 90, 1-7.	2.2	7
102	Serum neurofilament light chain predicts future freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 91, 102-104.	2.2	7
103	Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway. Neural Regeneration Research, 2013, 8, 3269-74.	3.0	7
104	Combined focal myoclonus and dystonia secondary to a cerebellar hemorrhage: a case report. BMC Neurology, 2016, 16, 228.	1.8	6
105	Pregnancy and Delivery in a Generalized Dystonia Patient Treated with Internal Globus Pallidal Deep Brain Stimulation: a Case Report. Journal of Korean Medical Science, 2017, 32, 155.	2.5	6
106	A 3-year observation of excessive daytime sleepiness after subthalamic deep brain stimulation in patients with Parkinson's disease. Clinical Neurology and Neurosurgery, 2020, 192, 105721.	1.4	6
107	Variability of FP-CIT PET Patterns Associated With Clinical Features of Multiple System Atrophy. Neurology, 2021, 96, e1663-e1671.	1.1	6
108	Dural Arteriovenous Fistula-Associated Reversible Parkinsonism with Presynaptic Dopaminergic Loss. Journal of Movement Disorders, 2015, 8, 141-143.	1.3	6

#	Article	IF	CITATIONS
109	Peripapillary retinal nerve fiber layer thinning in patients with progressive supranuclear palsy. Journal of Neurology, 2022, 269, 3216-3225.	3.6	6
110	Correlation of electrode position and clinical outcomes in globus pallidus stimulation for dystonia. Acta Neurochirurgica, 2017, 159, 1349-1355.	1.7	5
111	Chronological View of Peak and Diphasic Dyskinesia, Wearing Off and Freezing of Gait in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 741-747.	2.8	5
112	Negative α-synuclein pathology in the submandibular gland of patients carrying PRKN pathogenic variants. Parkinsonism and Related Disorders, 2020, 81, 179-182.	2.2	5
113	Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials. Journal of Neurology, 2022, 269, 62-71.	3.6	5
114	The probable REM sleep behavior disorder negatively affects health-related quality of life in Parkinson's disease with bilateral subthalamic nucleus stimulation. Parkinsonism and Related Disorders, 2020, 81, 136-139.	2.2	5
115	Patient-reported responses to medical treatment in primary dystonia. Journal of Clinical Neuroscience, 2020, 75, 242-244.	1.5	5
116	Arching deep brain stimulation in dystonia types. Journal of Neural Transmission, 2021, 128, 539-547.	2.8	5
117	Young-Onset Parkinson's Disease with Impulse Control Disorder Due to Novel Variants of F-Box Only Protein 7. Journal of Movement Disorders, 2020, 13, 225-228.	1.3	5
118	Late-Onset Langerhans Cell Histiocytosis with Cerebellar Ataxia as an Initial Symptom. Case Reports in Neurology, 2017, 8, 218-223.	0.7	4
119	Residual signs of dopa-responsive dystonia with GCH1 mutation following levodopa treatment are uncommon in Korean patients. Parkinsonism and Related Disorders, 2019, 65, 248-251.	2.2	4
120	Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinson's Disease. Neurodegenerative Diseases, 2019, 19, 171-177.	1.4	4
121	Patient selected goals and satisfaction after bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease. Journal of Clinical Neuroscience, 2020, 76, 148-153.	1.5	4
122	Effects of Deep Brain Stimulation on Sleep-Wake Disturbances in Patients with Parkinson's Disease: A Narrative Review. Current Neuropharmacology, 2021, 19, 1716-1727.	2.9	4
123	Can Therapeutic-Range Chronic Phenytoin Administration Cause Cerebellar Ataxia?. Journal of Epilepsy Research, 2017, 7, 21-24.	0.4	4
124	A Case of Adrenoleukodystrophy Presenting as Progressive Cerebellar Dysfunction. Journal of Movement Disorders, 2009, 2, 91-94.	1.3	4
125	Myotonia Congenita Can Be Mistaken as Paroxysmal Kinesigenic Dyskinesia. Journal of Movement Disorders, 2018, 11, 49-51.	1.3	4

126 Validation Study of the Official Korean Version of the Movement Disorder Society-Unified Parkinson's

#	ARTICLE	IF	CITATIONS
127	Automatic Measurement of Postural Abnormalities With a Pose Estimation Algorithm in Parkinson's Disease. Journal of Movement Disorders, 2022, 15, 140-145.	1.3	4
128	Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease. Parkinson's Disease, 2017, 2017, 1-8.	1.1	3
129	Determinants of Functional Independence or Its Loss following Subthalamic Nucleus Stimulation in Parkinson's Disease. Stereotactic and Functional Neurosurgery, 2019, 97, 106-112.	1.5	3
130	Prospective cohort study of patients with early gastric cancer to detect prodromal Parkinson disease (EGC-PPD): A study protocol and baseline characteristics. Journal of Clinical Neuroscience, 2019, 66, 26-32.	1.5	3
131	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. Journal of the Neurological Sciences, 2020, 418, 117105.	0.6	3
132	GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology. Journal of Neurology, 2020, 267, 1952-1959.	3.6	3
133	Gastric synucleinopathy as prodromal pathological biomarker in idiopathic REM sleep behaviour disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 450-451.	1.9	3
134	Bilateral subthalamic nucleus deep brain stimulation is an effective treatment for diphasic dyskinesia. European Journal of Neurology, 2021, 28, 1574-1580.	3.3	3
135	Potential Sex-Specific Effects of Apolipoprotein E ɛ4 on Cognitive Decline in Early Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 497-505.	2.8	3
136	Coexistence of dentatorubralâ€pallidoluysian atrophy and Parkinson's disease: An autopsy case report. Neuropathology, 2021, 41, 196-205.	1.2	3
137	Spinal Myoclonus Responding to Continuous Intrathecal Morphine Pump. Journal of Movement Disorders, 2017, 10, 158-160.	1.3	3
138	A Rare Case of Late Adult-Onset Niemann-Pick Disease Type C. Journal of Movement Disorders, 2020, 13, 163-165.	1.3	3
139	Clinical differences in patients with Parkinson's disease according to tandem gait performance. Journal of Clinical Neuroscience, 2019, 60, 93-95.	1.5	2
140	A Case of <i>PLA2G6</i> -Associated Neurodegeneration with Frequent Myoclonus And Generalized Onset Tonic-Clonic Seizures: Successful Treatment with Zonisamide. Journal of Clinical Neurology		

#	Article	IF	CITATIONS
145	Data-driven subtype classification of patients with early-stage multiple system atrophy. Parkinsonism and Related Disorders, 2022, 95, 92-97.	2.2	2
146	The effects of different anesthetic methods on neuronal activity and movement symptoms of Parkinson's disease. International Journal of Precision Engineering and Manufacturing, 2015, 16, 573-579.	2.2	1
147	The importance of clinical competence in an age of the more diagnostic tests the better. Journal of Clinical Neuroscience, 2017, 41, 170-171.	1.5	1
148	A case report of thoracolumbar paraspinal myopathy as the cause of camptocormia in a patient with atypical parkinsonism. BMC Neurology, 2017, 17, 118.	1.8	1
149	Dramatic psychiatric and behavioral symptoms following a subthalamic lesion. Journal of Clinical Neuroscience, 2018, 47, 154-156.	1.5	1
150	A Patient with Myotonic Dystrophy Type 1 Presenting as Parkinsonism. Journal of Movement Disorders, 2018, 11, 145-148.	1.3	1
151	An Autopsy Case of Progressive Supranuclear Palsy With Incidental <i>ATXN2</i> Expansion. JAMA Neurology, 2018, 75, 1025.	9.0	1
152	Tics in Paroxysmal Kinesigenic Dyskinesia. Movement Disorders Clinical Practice, 2019, 6, 502-503.	1.5	1
153	Musculoskeletal problems in PD patients have no association with socioeconomic status. Journal of Clinical Neuroscience, 2019, 70, 229-233.	1.5	1
154	Effect of unilateral subthalamic deep brain stimulation in highly asymmetrical Parkinson's disease: 7-year follow-up. Journal of Neurosurgery, 2019, 131, 1508-1513.	1.6	1
155	SLC20A2 mutation manifesting as very late-onset orofacial dyskinesia. Neurological Sciences, 2021, 42, 2561-2564.	1.9	1
156	Malignant Neuroleptic Syndrome following Deep Brain Stimulation Surgery of Globus Pallidus Pars Internus in Cerebral Palsy. Korean Journal of Critical Care Medicine, 2016, 31, 34.	0.1	1
157	Hypothyroidism-induced Reversible Encephalopathy as a Cause of Aggravation of Parkinsonism and Myoclonus in Parkinson's Disease. Tremor and Other Hyperkinetic Movements, 2017, 7, 505.	2.0	1
158	Familial Spinocerebellar Ataxia Type 2 Parkinsonism Presenting as Intractable Oromandibular Dystonia. Tremor and Other Hyperkinetic Movements, 2019, 9, 611.	2.0	1
159	Development of Clinical Milestones in Parkinson's Disease After Bilateral Subthalamic Deep Brain Stimulation. Journal of Movement Disorders, 2022, 15, 124-131.	1.3	1
160	Youngâ€onset multiple system atrophy: Its rarity and heterogeneity. Movement Disorders, 2019, 34, 1085-1086.	3.9	0
161	Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?. Movement Disorders, 2020, 35, 901-902.	3.9	0
162	Need for Registration and Reporting of Acupuncture Trials in Parkinson's Disease in Korea. Journal of Movement Disorders, 2017, 10, 130-134.	1.3	0